Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 18/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.55 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.55 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13615039 | 0.86 | SLC22A12 (0.65) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL13852841 | 0.85 | SLC22A12 (0.56) | SLC22A12CYP2C9CYP3A4BRD4 | |
| SCHEMBL13629426 | 0.84 | SLC22A12 (0.74) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL13615141 | 0.84 | SLC22A12 (0.54) | SLC22A12BRD4 | |
| SCHEMBL26075672 | 0.84 | SLC22A12 (0.69) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL13852804 | 0.83 | SLC22A12 (0.61) | SLC22A12CYP2C9SLC22A6SLC22A8SLC22A11 | |
| SCHEMBL13852848 | 0.82 | SLC22A12 (0.54) | SLC22A12BRD4AXL | |
| SCHEMBL13615274 | 0.79 | PTGES2 (0.52) | SLC22A12 | |
| SCHEMBL13615206 | 0.78 | FFAR4 (0.60) | SLC22A12CYP3A4BRD4 | |
| SCHEMBL13615168 | 0.78 | HSD17B2 (0.61) | SLC22A12CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-11-05 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | NOVARTIS AG | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118277-A1 | 3 Unsubstituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | SLC22A12 4663/4885CYP2C9 2081/4885SLC22A6 4708/4885 |
| US-20090275593-A1 | 3 Substituted N-(aryl- or heteroaryl)-pyrazolo[1,5-a]pyrimidines as Kinase Inhibitors | TIE1, TEK, MATK | SLC22A12 4627/4885CYP2C9 1828/4885SLC22A6 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.